Lilly’s triple agonist retatrutide delivered potent weight loss in pivotal Phase 3 obesity trials | Eli Lilly and Company
In the recent TRIUMPH-1 study, participants taking retatrutide (4 mg, 9 mg, and 12 mg) achieved clinically meaningful weight reduction across diverse age groups. With baseline BMI ≥35, most individuals continued to lose weight, with 85% achieving average 85 lbs over 104 weeks. Adverse events were generally mild, and discontinuation rates due to side effects were low.
TRIUMPH-1 highlights the importance of personalized treatment options for adults with obesity or overweight, emphasizing how retatrutide offers a unique combination of GLP-1 and glucagon. From 4 mg to 12 mg, patients saw consistent improvements in cardiometabolic health and weight management. The trial extension showed remarkable outcomes for those with severe obesity, with 65% achieving BMI <30, underscoring the potential of retatrutide to address both metabolic and physical health challenges.
For clinical relevance, retatrutide’s safety profile supports its use in obese populations, while its dual action promotes better long-term outcomes. Experts like Ania Jastreboff emphasize that retatrutide provides a targeted approach to obesity, complementing existing therapies. Future studies aim to expand its application beyond current indications, further refining its role in treating metabolic disorders.
This research underscores the evolving landscape of obesity treatment, where innovative approaches like retatrutide offer new possibilities for patients seeking effective, safe, and patient-centered solutions.
